The American Society of Oncology (ASCO) 2020 Annual Meeting was held virtually this year due to the ongoing COVID-19 pandemic. Although the meeting was virtual, the programme was full of the latest data, ongoing controversies in the field and updates on potential new treatments for cancer.
Hot topics at this year’s meeting included immunotherapy, COVID-19 and cancer, developmental therapeutics and care delivery. Data were presented from the latest clinical trials including ADAURA, JAVELIN , E2108 and KEYNOTE-177.
View all videosASCO 2020
VIDEO: SAFIR02-IMMUNO: PDL1 copy number changes predicts checkpoint blockade inhibitor efficacy in mBC w/ Thomas Bachelot w/ @CLCCLeonBerard: http://ow.ly/5ZDZ50AuLdP
@VJOncology @myESMO #BCsm #VirtualMeeting #ESMOBreast20 #OncoAlert @OncoAlert #BreastCancer #ImmunoOnc
You think it’s dull to read tweets about the @myESMO 🤝 @OncoAlert 🚨 “Social Media & Virtual Meetings in the #COVID19 Era” survey?
Consider yourself lucky bc instead you can watch (‼️) #OncoAlert mastermind @weoncologists explain the whole thing in this (👇) @VJOncology video! https://twitter.com/vjoncology/status/1283072388209483777
Gil Morgan tells us about the joint @OncoAlert and @myESMO collaboration survey looking at ‘Social Media & Virtual Meetings in the #COVID19 Era’
Have your say here! 👉http://ow.ly/xWBb50Ay5wv👈
@weoncologists #OncoAlert @OncoAlert #VirtualMeeting @VJOncology
#PYROTINIB EN #NSCLC AVANZADO HER2-MUTADO, PREVIO TRATAMIENTO CON #QUIMIOTERAPIA
https://www.esmo.org/oncology-news/pyrotinib-in-her2-mutated-advanced-nsclc-previously-treated-with-chemotherapy?hit=some
@Dunson30612519 @school_latin @GOncologia @ManuelDomine @MarianaBrandao0 @OPENoncology @susanahprieto @VJOncology @jillfeldman4 @dokter_onkologi @AnnaFaragoMD @myESMO https://twitter.com/myESMO/status/1282895118773686275
Pyrotinib in HER2-mutated advanced #NSCLC previously treated with #chemotherapy: Promising antitumour activity & acceptable safety profile in #cancerpatients. A global, multicentre, randomised Ph3 III planned 🔎 http://ow.ly/4RcO50AwuT7 #oncologynews #cancerresearch #lcsm
ASCO 2020
The American Society of Oncology (ASCO) 2020 Annual Meeting was held virtually this year due to the ongoing COVID-19 pandemic. Although the meeting was virtual, the programme was full of the latest data, ongoing controversies in the field and updates on potential new treatments for cancer.
Hot topics at this year’s meeting included immunotherapy, COVID-19 and cancer, developmental therapeutics and care delivery. Data were presented from the latest clinical trials including ADAURA, JAVELIN , E2108 and KEYNOTE-177.
View all videosVIDEO: SAFIR02-IMMUNO: PDL1 copy number changes predicts checkpoint blockade inhibitor efficacy in mBC w/ Thomas Bachelot w/ @CLCCLeonBerard: http://ow.ly/5ZDZ50AuLdP
@VJOncology @myESMO #BCsm #VirtualMeeting #ESMOBreast20 #OncoAlert @OncoAlert #BreastCancer #ImmunoOnc
You think it’s dull to read tweets about the @myESMO 🤝 @OncoAlert 🚨 “Social Media & Virtual Meetings in the #COVID19 Era” survey?
Consider yourself lucky bc instead you can watch (‼️) #OncoAlert mastermind @weoncologists explain the whole thing in this (👇) @VJOncology video! https://twitter.com/vjoncology/status/1283072388209483777
Gil Morgan tells us about the joint @OncoAlert and @myESMO collaboration survey looking at ‘Social Media & Virtual Meetings in the #COVID19 Era’
Have your say here! 👉http://ow.ly/xWBb50Ay5wv👈
@weoncologists #OncoAlert @OncoAlert #VirtualMeeting @VJOncology
#PYROTINIB EN #NSCLC AVANZADO HER2-MUTADO, PREVIO TRATAMIENTO CON #QUIMIOTERAPIA
https://www.esmo.org/oncology-news/pyrotinib-in-her2-mutated-advanced-nsclc-previously-treated-with-chemotherapy?hit=some
@Dunson30612519 @school_latin @GOncologia @ManuelDomine @MarianaBrandao0 @OPENoncology @susanahprieto @VJOncology @jillfeldman4 @dokter_onkologi @AnnaFaragoMD @myESMO https://twitter.com/myESMO/status/1282895118773686275
Pyrotinib in HER2-mutated advanced #NSCLC previously treated with #chemotherapy: Promising antitumour activity & acceptable safety profile in #cancerpatients. A global, multicentre, randomised Ph3 III planned 🔎 http://ow.ly/4RcO50AwuT7 #oncologynews #cancerresearch #lcsm
